VOGX (Vogenx) EV-to-EBIT: (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VOGX Vogenx Inc VOGX
8 GF Score
Price $14.09
View Full Analysis

What is Vogenx EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vogenx's Enterprise Value is $196.52 Mil. Vogenx does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vogenx's EV-to-EBIT at this moment.

The historical rank and industry rank for Vogenx's EV-to-EBIT or its related term are showing as below:

VOGX' s EV-to-EBIT Range Over the Past 10 Years
Min: -136.56   Med: 0   Max: 0
Current: -136.56
VOGX's EV-to-EBIT is ranked worse than
100% of 368 companies
in the Biotechnology industry
Industry Median: 15.71 vs VOGX: -136.56

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Vogenx's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil. Vogenx does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vogenx's Earnings Yield (Joel Greenblatt) % at this moment.

Vogenx  (NAS:VOGX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Vogenx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2025 ) =EBIT / Enterprise Value (Q: Dec. 2025 )
=/0
= %

Vogenx EV-to-EBIT Related Terms

Vogenx EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Vogenx's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vogenx EV-to-EBIT Chart

Vogenx Annual Data
Trend Dec24 Dec25
EV-to-EBIT
0.00 0.00

Vogenx Semi-Annual Data
Dec24 Dec25
EV-to-EBIT 0.00 0.00

VOGX vs : EV-to-EBIT Comparison

For the Biotechnology subindustry, Vogenx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vogenx EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vogenx's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vogenx's EV-to-EBIT falls into.


VOGX
8GF Score
Vogenx Inc VOGX
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vogenx EV-to-EBIT Calculation

Vogenx's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=196.517/
=

Vogenx Business Description

Comparable Companies
Address 3901 Barrett Drive, P.O. Box 19469, Suite 300, Raleigh, NC, USA, 27609
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
8GF Score

Get the complete analysis for VOGX

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.09
Price